HC Wainwright Boosts Earnings Estimates for Mural Oncology

Mural Oncology plc (NASDAQ:MURA) – Equities researchers at HC Wainwright raised their FY2024 EPS estimates for Mural Oncology in a research note issued on Wednesday, November 13th. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnings of ($7.59) per share for the year, up from their prior estimate of ($7.85). HC Wainwright currently has a “Buy” rating and a $18.00 target price on the stock. The consensus estimate for Mural Oncology’s current full-year earnings is ($7.54) per share. HC Wainwright also issued estimates for Mural Oncology’s Q4 2024 earnings at ($2.03) EPS, Q1 2025 earnings at ($2.05) EPS, Q2 2025 earnings at ($1.19) EPS, Q3 2025 earnings at ($1.08) EPS, Q4 2025 earnings at ($0.99) EPS, FY2025 earnings at ($5.32) EPS, FY2026 earnings at ($3.31) EPS, FY2027 earnings at ($2.19) EPS and FY2028 earnings at ($1.65) EPS.

Separately, Raymond James began coverage on Mural Oncology in a research report on Friday, October 4th. They set a “strong-buy” rating and a $18.00 price objective for the company.

Mural Oncology Trading Down 2.6 %

Shares of MURA opened at $3.36 on Monday. The stock’s 50-day moving average price is $3.40 and its two-hundred day moving average price is $3.37. Mural Oncology has a 12 month low of $2.88 and a 12 month high of $6.25. The company has a market capitalization of $57.19 million and a PE ratio of -0.37.

Insider Buying and Selling at Mural Oncology

In other Mural Oncology news, CFO Adam D. Cutler sold 7,421 shares of Mural Oncology stock in a transaction that occurred on Thursday, October 31st. The stock was sold at an average price of $3.41, for a total value of $25,305.61. Following the completion of the sale, the chief financial officer now directly owns 71,438 shares in the company, valued at approximately $243,603.58. The trade was a 9.41 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.06% of the company’s stock.

Hedge Funds Weigh In On Mural Oncology

Institutional investors and hedge funds have recently modified their holdings of the business. BBR Partners LLC acquired a new position in shares of Mural Oncology during the 2nd quarter valued at $31,000. Rhumbline Advisers acquired a new position in shares of Mural Oncology during the second quarter valued at about $34,000. Commerce Bank bought a new position in shares of Mural Oncology during the 3rd quarter worth about $39,000. FMR LLC grew its stake in shares of Mural Oncology by 124.7% in the 3rd quarter. FMR LLC now owns 20,580 shares of the company’s stock valued at $64,000 after buying an additional 11,423 shares during the period. Finally, Canada Pension Plan Investment Board bought a new stake in Mural Oncology in the 2nd quarter valued at about $70,000. 80.21% of the stock is currently owned by institutional investors.

About Mural Oncology

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.